NEOGAP Therapeutics AB

Our CEO in action at the "Aiming for the clinics"-conference at SciLifeLab in Uppsala today.

  Our CEO, Samuel Svensson, will share insights from our journey in developing the cell therapy,  pTTL, at the upcoming “Aiming for the clinics”  conference in Uppsala on Wednesday, 8 May. The conference is organised by SciLifeLab and Uppsala Clinical Research Center (UCR) .   “Taking an innovative and truly personalised product from the initial innovation stage all the way through to clinical trials is a true challenge but also very rewarding. Great science, combined with a highly competent team, skilled collaborators, and a strong focus are our keys to success,” says Samuel Svensson.   Neogap is developing pTTL, personalised Tumour Trained Lymphocytes, a tailored cell therapy that utilises modified proteins, known as neoantigens, to specifically target and activate the immune system against cancer cells. This cutting-edge therapy is currently being assessed in phase I/II clinical trials for the treatment of colorectal cancer.   For more information, visit https://lnkd.in/eKitmrEY   #immunotherapy #personalisedimmunotherapy #celltherapy #clinicaltrials #neogaptherapeutics

We are thrilled to showcase Neogap’s advancements in cancer treatment with our personalised Tumour Trained Lymphocytes (pTTL) at the upcoming 7th International Neoantigen Summit in Amsterdam. Our innovative approach involves using T cells from the patient's own lymph nodes. These T cells are expanded in vitro and activated to target tumour-specific neoantigens, identified by our PIOR® Manufacturing system, and presented to the T cells using our EpiTCer® beads technology.   Our EpiTCer® beads platform is cutting-edge technology, offering a unique way to kick-start the immune system to obtain tumour-trained T cells. The EpiTCer® beads may also be used in a potency assay approach that can be applied to the characterisation of clinical material from patients with cancer. This will play a crucial role in refining the application and efficacy of our cell therapy pTTL.   📍 Join us on Wednesday, 1st May in Amsterdam to learn how our pioneering approach is setting new benchmarks in adoptive T-cell therapy within the world of neoantigens. Connect with Luigi Notari for deeper insights into our therapy.   We look forward to the opportunity to meet and engage with fellow professionals in the field and share more about our groundbreaking research.   #immunotherapy #personalisedimmunotherapy #celltherapy #neoantigens #neogaptherapeutics

We are proud to welcome Dr. Vilma Urbonaviciute to the Neogap team!   Vilma is an experienced research scientist with over 20 years of immunology experience, specialising in T cell tolerance. Her dedication lies in the translational aspects of fundamental research, aiming to transform basic scientific discoveries into novel therapies based on immune cell biology.   Her passion for designing bioassays to tackle complex research questions, coupled with her expertise in creating tools to advance the understanding and monitoring of health and disease, has already established her as a valued and respected member of the Cell Therapy Development Team.   Throughout her career, Vilma has held various scientific and managerial roles across academia and the pharmaceutical sector, at esteemed institutions such as Vilnius University (Lithuania), University of Erlangen-Nuremberg and Fraunhofer Society (Germany), Karolinska Institute, Genagon Therapeutics, and CarryGenes (Sweden).   Initially joining Neogap to fill a temporary role, Vilma has, over the past seven months, significantly advanced our efforts in developing a potency assay approach. This work is critical to ensuring the quality of Neogap's drug product, pTTL, aimed at treating solid tumors. As a Senior Scientist at Neogap Therapeutics, Vilma will continue leading the potency assay development efforts, adding considerable value to an already strong team.   A warm welcome, Vilma! 🌟   #immunotherapy #personalisedimmunotherapy #cancertreatment #biotechnology #neogaptherapeutics

We’re delighted to welcome Kristine Bylund as our new Head of Cell Therapy Development! With over 25 years of experience in project and laboratory management and a strong background in molecular biology, Kristine brings a wealth of expertise to our team. Kristine has been a valuable consultant with us since last autumn, contributing significantly to various projects and initiatives. Her extensive experience includes work at esteemed institutions such as the Medical College of Wisconsin (USA), Novartis, the Friedrich Miescher Institute (Basel, Switzerland), the Karolinska Institute, AstraZeneca (Sweden) and Procella Therapeutics (Sweden). As Head of Cell Therapy Development, Kristine will lead the team through the current study and ensure manufacturing readiness for the next step, positioning us at the forefront of cell therapy advancements. Please join us in welcoming Kristine to the Neogap team! 🎉 #immunotherapy #personalisedimmunotherapy #cancertreatment #biotechnology #neogaptherapeutics

Bioteknikbolaget NEOGAP Therapeutics AB får fem miljoner kronor från EU-programmet Eurostars för utveckling av en analysmetod för T-cellsaktivitet mot tumörer som sker i samarbete med franska Okomera.

🚀 We are proud to announce that Neogap has received a SEK 5 million grant from Eurostars for a project aimed at developing an advanced analysis method for T-cell activity against cancer. The project is a collaboration with Okomera and will enhance our understanding of T-cell interactions with tumour cells, paving the way for more effective cancer treatments.   "We are very grateful for Eurostars' support, which recognises our innovative efforts in cell therapy analysis and enables further research that is essential for advancing our cell therapy product to later clinical phases," says Samuel Svensson , CEO of Neogap Therapeutics.   Read the full press release in English here: https://lnkd.in/dqQaGyu9   #neogaptherapeutics #immunotherapy #cancertreatment #eurostars #funding  https://lnkd.in/duzsYj_V

Neogap participated in Cell Therapy Potency Assay Summit in Boston last week, where Vilma Urbonaviciute, PhD and Kristine Bylund presented our latest work on personalised Tumour Trained Lymphocytes (pTTL) for cancer treatment. For a comprehensive look at our poster and insights into how these developments are shaping the future of cell therapy, visit: https://neogap.se/news/ #immunotherapy #personalisedimmunotherapy #celltherapy #potencyassay #neogaptherapeutics

Neogap is honoured to have our founder and Chief Scientific Officer, Hans Grönlund, presenting at the Harald zur Hausen Memorial Symposium at DKFZ German Cancer Research Center in Heidelberg today. His participation, being the only Northern European speaker, underscores the innovative work Neogap is doing in the field of cancer research.    This symposium, a tribute to Nobel Laureate Harald zur Hausen, highlights significant advancements in cancer research, a mission closely aligned with our own. Hans Grönlund’s insights into targeted immunotherapy and precision diagnostics are key to advancing cancer treatment, reflecting both his and Neogap's commitment to this critical field.   "Harald zur Hausen's groundbreaking work on human papillomavirus vaccinations has been instrumental in preventing cancer in women, promising to save hundreds of thousands of lives in the coming decades. As a scientist and a father of three vaccinated daughters, I am deeply moved by the profound impact of his research," says Hans Grönlund.    Please join us in acknowledging this important contribution to the ongoing evolution of cancer treatment.   #immunotherapy #precisiondiagnostics #cancertreatment #biotechnology #neogaptherapeutics  

Professor Abbas Chabok, Principal Investigator for Surgery Site Västmanlands sjukhus, today presenting our ongoing clinical trial Neogap-CRC-01 at Regiondag Kirurgi och Onkologi to an engaged audience of specialists within the field. Neogap-CRC-01 is a phase I/II clinical study in stage 4 colorectal cancer that is currently recruiting. In this study, T cells from the patient's own lymph nodes are expanded in vitro to target tumour-specific neoantigens with the aid of our EpiTCer® bead technology and given back to the patient as a one dose infusion. Interested in knowing more about the study or the science? Please visit our homepage: https://neogap.se/ and https://lnkd.in/dgi7_SXN